Europe Orphan Drug Market To Surpass USD 50 Billion by 2018

More than 300 orphan designated drugs are in clinical pipeline & 130 orphan drugs are marketed in Europe.

Release Date: 13-Aug-2014



“Europe Orphan Drug Market Outlook 2018” Report Highlight:

 

The concept of rare diseases and the idea that a special attention needs to be given to this sector has been taking shape in Europe since the 1990s. ever since then the political aspects and initiatives related to orphan medicinal products have been emerging at both the EU level and at the level of member states individually.

Europe is the second largest market for orphan drugs. In the European region, rare disease is considered to be a priority area and research in this field is given high importance by the EU Framework Programmes for Research and Technological Development (FP) ever since the early 1990s. Increasing the utilization of scarce resources and coordinating research efforts are the basic factors which have been responsible for success in the European rare diseases market. However, the absence of an exhaustive rare disease classification, standard terms of reference and a harmonized regulatory requirement, has always been a challenge in this region, which is currently impacting the global sharing of information, data and samples which would boost the research further.

The orphan drugs enjoy significant competitive advantages in the market owing to the market exclusivity period after the drug has been authorized. Through this clause, the manufacturer of orphan drugs is given a monopoly status in the market because according to the law, no other company is allowed to market the orphan drugs during the exclusivity period. Additionally, this monopolistic power is further strengthened with the fact that no other alternative health technology exists for many orphan drugs.

 

For Report Sample Visit: “Europe Orphan Drug Market Outlook 2018”

 

Or Contact: avinash@kuickresearch.com

 

Need custom market research solution? We can help you with that too.